Study · Non-randomized trial · n = 36 · 2015

6 results

Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.

Jensterle M, Kocjan T, Kravos NA, Pfeifer M, Janez A

Endocrine research20 Oct 2014Cited by 66 (Europe PMC)

PMID25330463DOI10.3109/07435800.2014.966385PepBankPUB-25330463

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In obese women with PCOS, 12 weeks of liraglutide gave an average weight loss of 3.8 kg.
In plain wordsIn obese women with PCOS, 12 weeks of liraglutide led to an average weight loss of 3.8 kg.
Peptide
Liraglutide
Outcome
DecreaseBody weight loss
Study
n = 36
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Weight loss
3.8 kg
liraglutide
Source sentences
Summary
Subjects treated with liraglutide lost on average 3.8 ± 0.1 kg (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-six obese women with PCOS (mean ± SD, aged 31.2 ± 7.8 years, with BMI 38.7 ± 0.1 kg/m(2)), pretreated with metformin (1000 mg BID) were switched to liraglutide 1.2 mg QD sc for 12 weeks.
Report a problemFND-2533046301
02HumanNon-randomized trialEfficacy outcome
In obese women with PCOS, liraglutide significantly reduced waist circumference.
In plain wordsIn obese women with PCOS, liraglutide reduced waist size.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference
Study
n = 36
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Significant reductions of waist circumference and visceral adipose tissue (VAT) mass, volume and area were demonstrated from liraglutide induction to the end of the study.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-six obese women with PCOS (mean ± SD, aged 31.2 ± 7.8 years, with BMI 38.7 ± 0.1 kg/m(2)), pretreated with metformin (1000 mg BID) were switched to liraglutide 1.2 mg QD sc for 12 weeks.
Report a problemFND-2533046302
03HumanNon-randomized trialEfficacy outcome
In obese women with PCOS, liraglutide significantly reduced visceral adipose tissue mass, volume and area.
In plain wordsIn obese women with PCOS, liraglutide reduced belly fat.
Peptide
Liraglutide
Outcome
DecreaseVisceral adipose tissue mass, volume and area
Study
n = 36
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Significant reductions of waist circumference and visceral adipose tissue (VAT) mass, volume and area were demonstrated from liraglutide induction to the end of the study.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-six obese women with PCOS (mean ± SD, aged 31.2 ± 7.8 years, with BMI 38.7 ± 0.1 kg/m(2)), pretreated with metformin (1000 mg BID) were switched to liraglutide 1.2 mg QD sc for 12 weeks.
Report a problemFND-2533046303
04HumanNon-randomized trialEfficacy outcome
In obese women with PCOS, the uncontrolled eating score decreased with liraglutide from 36.8 to 19.6.
In plain wordsIn obese women with PCOS, liraglutide lowered the uncontrolled eating score.
Peptide
Liraglutide
Outcome
DecreaseUncontrolled eating score
Study
n = 36
Outcome group
Appetite and food intake · Mental health and mood
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Uncontrolled eating score
36.8 points
baseline
Uncontrolled eating score
19.6 points
after liraglutide
Source sentences
Summary
After treatment with liraglutide the uncontrolled eating (UE) score decreased from 36.8 ± 24.5 to 19.6 ± 18.4 (p < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-six obese women with PCOS (mean ± SD, aged 31.2 ± 7.8 years, with BMI 38.7 ± 0.1 kg/m(2)), pretreated with metformin (1000 mg BID) were switched to liraglutide 1.2 mg QD sc for 12 weeks.
Report a problemFND-2533046304
05HumanNon-randomized trialEfficacy outcome
In obese women with PCOS, the emotional eating score decreased with liraglutide from 49.9 to 28.5.
In plain wordsIn obese women with PCOS, liraglutide lowered the emotional eating score.
Peptide
Liraglutide
Outcome
DecreaseEmotional eating score
Study
n = 36
Outcome group
Appetite and food intake · Mental health and mood
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Emotional eating score
49.9 points
baseline
Emotional eating score
28.5 points
after liraglutide
Source sentences
Summary
emotional eating (EE) score decreased from 49.9 ± 33.3 to 28.5 ± 26.9 (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-six obese women with PCOS (mean ± SD, aged 31.2 ± 7.8 years, with BMI 38.7 ± 0.1 kg/m(2)), pretreated with metformin (1000 mg BID) were switched to liraglutide 1.2 mg QD sc for 12 weeks.
Report a problemFND-2533046305
06HumanNon-randomized trialEfficacy outcome
In obese women with PCOS, cognitive restraint scores did not change with liraglutide.
In plain wordsIn obese women with PCOS, liraglutide did not change the cognitive restraint eating score.
Peptide
Liraglutide
Outcome
No significant changeCognitive restraint score
Study
n = 36
Outcome group
Appetite and food intake · Mental health and mood
Studied dose
1.2 mg QD · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Scores for cognitive restraint (CR) were not changed.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-six obese women with PCOS (mean ± SD, aged 31.2 ± 7.8 years, with BMI 38.7 ± 0.1 kg/m(2)), pretreated with metformin (1000 mg BID) were switched to liraglutide 1.2 mg QD sc for 12 weeks.
Report a problemFND-2533046306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT06243536

The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients

University Hospital Sestre Milosrdnicen = 60est. 1 Feb 2024 to est. 31 Dec 2024

Type 2 Diabetes · Overweight · Disordered Eating Behaviors

Trial page ClinicalTrials.govUpdated 6 Feb 2024

CompletedPhase 4NCT03352869

Research of Exenatide for Overweight/Obese PCOS Patients With IGR

RenJi Hospitaln = 18328 Nov 2017 to 31 Jul 2018

Polycystic Ovary Syndrome · Overweight and Obesity · Disorder of Glucose Regulation

Trial page ClinicalTrials.govUpdated 11 Sept 2019

CompletedPhase 4NCT01911468

Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin

University Medical Centre Ljubljanan = 36Nov 2011 to Apr 2013

PCOS · Obesity

Trial page ClinicalTrials.govUpdated 30 Jul 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.